Compounds disrupting STOML3 oligomerisation prevented mechanical allodynia not only in nerve injury models, but also in a model of diabetic neuropathy [81], which raises hopes of possibly developing this therapeutic avenue for treating patients with diabetic neuropathy who experience a range of disturbances in mechanosensitivity, including dynamic mechanical allodynia [82]. Here, STOML3 is linked to diabetic neuropathy.